These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22730364)

  • 1. Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.
    Curtis JR; Yun H; Lange JL; Matthews R; Sharma P; Saag KG; Delzell E
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1855-63. PubMed ID: 22730364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
    Cadarette SM; Solomon DH; Katz JN; Patrick AR; Brookhart MA
    Osteoporos Int; 2011 Mar; 22(3):943-54. PubMed ID: 20532481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
    Modi A; Tang J; Sen S; Díez-Pérez A
    Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.
    Butt DA; Mamdani M; Gomes T; Lix L; Lu H; Tu K;
    J Bone Miner Res; 2014 Nov; 29(11):2483-8. PubMed ID: 24806397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.
    Curtis JR; Delzell E; Chen L; Black D; Ensrud K; Judd S; Safford MM; Schwartz AV; Bauer DC
    J Bone Miner Res; 2011 Apr; 26(4):683-8. PubMed ID: 20939064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
    Wang Z; Ward MM; Chan L; Bhattacharyya T
    Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.
    Kwok T; Leung J; Barrett-Connor E;
    Age Ageing; 2017 Jan; 46(1):57-64. PubMed ID: 28181652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
    Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
    J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for older men with fractures.
    Shepherd AJ; Cass AR; Ray LA; Tan A; Wilkinson GS
    Osteoporos Int; 2012 Mar; 23(3):1041-51. PubMed ID: 21811867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
    Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
    Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
    Pazianas M; Abrahamsen B; Wang Y; Russell RG
    Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study.
    Kim SC; Kim MS; Sanfélix-Gimeno G; Song HJ; Liu J; Hurtado I; Peiró S; Lee J; Choi NK; Park BJ; Avorn J
    Am J Med; 2015 May; 128(5):519-26.e1. PubMed ID: 25660252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
    Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
    Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.